The serotonergic system in Parkinson's disease

172Citations
Citations of this article
246Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Although the cardinal manifestations of Parkinson's disease (PD) are attributed to a decline in dopamine levels in the striatum, a breadth of non-motor features and treatment-related complications in which the serotonergic system plays a pivotal role are increasingly recognised. Serotonin (5-HT)-mediated neurotransmission is altered in PD and the roles of the different 5-HT receptor subtypes in disease manifestations have been investigated. The aims of this article are to summarise and discuss all published preclinical and clinical studies that have investigated the serotonergic system in PD and related animal models, in order to recapitulate the state of the current knowledge and to identify areas that need further research and understanding. © 2011.

Cite

CITATION STYLE

APA

Huot, P., Fox, S. H., & Brotchie, J. M. (2011, October). The serotonergic system in Parkinson’s disease. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2011.08.004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free